Post-authorization observational, prospective, follow-up study of a cohort of patients with non-valvular atrial fibrillation who are treated with direct oral anticoagulants (DOACs) to evaluate the clinical course (occurrence of stroke, major bleeding and mortality) and its correlation with clinical, pharmacokinetic (plasma concentrations), pharmacodynamic (haemostatic) and pharmacogenetic factors.
Post-authorization observational, prospective, follow-up study of a cohort of patients with non-valvular atrial fibrillation treated with direct oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban) to assess the clinical course (occurrence of stroke, other ischemic or bleeding events and mortality) and its correlation with clinical, pharmacokinetic (plasma concentrations), pharmacodynamic (haemostatic) and pharmacogenetic factors. Patient selection and follow-up will be performed in 6 public Spanish hospitals: Hospital Universitario de la Princesa, Hospital Universitario La Paz, Hospital Universitario Ramón y Cajal, Fundación Jiménez Díaz, Hospital Gómez Ulla (Madrid) and Hospital Universitario de Burgos (Burgos). To reduce variability, the determination of anticoagulant activity will be performed in the Hematology Service of the Hospital Universitario de Burgos and the measurement of plasma concentrations and genotyping of all patients in the Clinical Pharmacology Service of the Hospital Universitario de la Princesa. Patients who are to receive or are receiving one of the four DOACs currently available in Spain will be informed about the characteristics of this study and will be asked to sign the consent form for their participation. The treatment or clinical management of these patients at each centre will not be modified. They will be asked three blood samples, coinciding with other tests that will be carried out to monitor their pathology (one blood sample for the study of the effect on coagulation, another for drug quantification in plasma and another for genetic studies) with the only requirement that they must have been treated with the drug for at least one week so that they have spent more than 5 half-lives and are in steady state. The samples will be extracted in the morning, before medication intake (trough concentrations).
Study Type
OBSERVATIONAL
Enrollment
700
Drug indicated for the treatment of NVAF
Drug indicated for the treatment of NVAF
Drug indicated for the treatment of NVAF
Hospital Universitario de Burgos
Burgos, Spain
Hospital Universitario de La Princesa
Madrid, Spain
Hospital Gómez Ulla
Madrid, Spain
Hospital Universitario Ramón y Cajal
Madrid, Spain
Major haemorrhages
Occurrence of haemorrhages will be monitored throughout the follow-up, i.e. for at least 15 months and up to 30.
Time frame: Throughout the follow-up, i.e. for at least 15 months and up to 30.
Haemorragic stroke
Occurrence of haemorragic stroke will be monitored throughout the follow-up i.e. for at least 15 months and up to 30..
Time frame: Throughout the follow-up, i.e. for at least 15 months and up to 30.
Ischemic stroke
Occurrence of ischemic stroke will be monitored throughout the follow-up i.e. for at least 15 months and up to 30..
Time frame: Throughout the follow-up, i.e. for at least 15 months and up to 30.
Death
All-cause mortality will be monitored throughout the follow-up i.e. for at least 15 months and up to 30..
Time frame: Throughout the follow-up, i.e. for at least 15 months and up to 30.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Drug indicated for the treatment of NVAF
Hospital Universitario Fundación Jiménez Díaz:
Madrid, Spain
Hospital Universitario de La Paz
Madrid, Spain